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Neurobiology of Disease

Controlled Cortical Impact Traumatic Brain Injury in
3xTg-AD Mice Causes Acute Intra-Axonal Amyloid-␤
Accumulation and Independently Accelerates the
Development of Tau Abnormalities
Hien T. Tran,1 Frank M. LaFerla,4 David M. Holtzman,1,2,3 and David L. Brody1,3
1

Department of Neurology, 2Department of Developmental Biology and Anatomy, and 3Hope Center for Neurological Disorders, Washington University in
St. Louis, St. Louis, Missouri 63110, 4Department of Neurobiology and Behavior, University of California, Irvine, California 92697

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized pathologically by progressive neuronal loss, extracellular
plaques containing the amyloid-␤ (A␤) peptides, and neurofibrillary tangles composed of hyperphosphorylated tau proteins. A␤ is
thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state. One of the major risk factors for AD is
traumatic brain injury (TBI). Acute intra-axonal A␤ and diffuse extracellular plaques occur in ⬃30% of human subjects after severe TBI.
Intra-axonal accumulations of tau but not tangle-like pathologies have also been found in these patients. Whether and how these acute
accumulations contribute to subsequent AD development is not known, and the interaction between A␤ and tau in the setting of TBI has
not been investigated. Here, we report that controlled cortical impact TBI in 3xTg-AD mice resulted in intra-axonal A␤ accumulations
and increased phospho-tau immunoreactivity at 24 h and up to 7 d after TBI. Given these findings, we investigated the relationship
between A␤ and tau pathologies after trauma in this model by systemic treatment of Compound E to inhibit ␥-secretase activity, a
proteolytic process required for A␤ production. Compound E treatment successfully blocked posttraumatic A␤ accumulation in these
injured mice at both time points. However, tau pathology was not affected. Our data support a causal role for TBI in acceleration of
AD-related pathologies and suggest that TBI may independently affect A␤ and tau abnormalities. Future studies will be required to assess
the behavioral and long-term neurodegenerative consequences of these pathologies.

Introduction
Traumatic brain injury (TBI) can increase the risk for subsequent
development of dementia of the Alzheimer’s type (Mortimer et
al., 1991; Nemetz et al., 1999; Plassman et al., 2000; Fleminger et
al., 2003). Pathological hallmarks of Alzheimer’s disease (AD) are
extracellular plaques containing the amyloid-␤ (A␤) peptides
and neurofibrillary tangles (NFTs) containing hyperphosphorylated tau proteins.
In mouse models of AD, A␤ pathology appears to be upstream
of tau pathology. Three lines of experimental evidence support
this relationship. First, intracerebral injections of aggregated A␤
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increased tau phosphorylation and therefore numbers of NFTs in
TauP310L transgenic mice at both local and distant regions (Gotz
et al., 2001). Second, double-transgenic mice expressing both
mutant APP and tau developed greater tau pathology than single
tau transgenic mice (Lewis et al., 2001; Perez et al., 2005; Hurtado
et al., 2010). Third, intracerebral injections of anti-A␤ antibodies
in 3xTg-AD mice reduced both A␤ and tau pathology. A␤ pathology then recurred, followed by later recurrence of tau pathology
(Oddo et al., 2004).
On the other hand, the human pathological literature suggests
that A␤ and tau pathologies may be independent in the setting of
TBI, or at least that the relationship may be more complex. First,
in single severe TBI, intra-axonal A␤ and diffuse extracellular
plaques occurred in about 30% of subjects (Roberts et al., 1991,
1994; Uryu et al., 2007). Intra-axonal accumulations of total and
phospho-tau, but not true NFT pathology, have been documented in a smaller number of cases (C. Smith et al., 2003; Ikonomovic et al., 2004; Uryu et al., 2007). In repetitive concussive
TBI resulting in dementia pugilistica or chronic traumatic
encephalopathy, the opposite relationship was found; 100% of
cases reported to date have had widespread NFTs, but a
smaller subset had A␤ pathology (Corsellis and Brierley, 1959;
Corsellis, 1989; Roberts et al., 1990; Tokuda et al., 1991; Geddes et al., 1996, 1999; Schmidt et al., 2001; McKee et al., 2009).
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Even when both pathologies were present, there was no indication that they colocalized.
To investigate the relationship between A␤ and tau pathologies in the setting of TBI, we performed controlled cortical impact
TBI in a mouse model of Alzheimer’s disease, called 3xTg-AD. In
the absence of injury, these mice develop intracellular A␤ accumulation starting at 2 months, intracellular tau immunoreactivity at 6 months, extracellular A␤ deposition at 15–26 months, and
tau-containing neurofibrillary tangles at 26 months (Oddo et al.,
2003, 2006; Mastrangelo and Bowers, 2008). Here, we show that
controlled cortical impact TBI independently results in intraaxonal A␤ and tau accumulation and increased tau phosphorylation in 3xTg-AD mice. This model may be a useful tool for
many mechanistic and preclinical therapeutic investigations into
the association between TBI and Alzheimer’s disease.

Materials and Methods
Animals. We used 5- to 7-month-old homozygous 3xTg-AD mice (Oddo
et al., 2003) of both sexes on a B6/SJV129 background and wild-type
B6/SJL mice. 3xTg-AD mice used in these experiments were derived from
founders received from the LaFerla laboratory in 2007. A␤ and tau pathologies have been stable since that time, with no evidence of drift. Mice
were housed in standard cages in a 12 h light/dark cycle and given food
and water ad libitum. All experiments were approved by the animal studies committee at Washington University in St Louis.
Controlled cortical impact experimental TBI. The experimental TBI
methods used in this study were performed as described previously
(Brody et al., 2007; Mac Donald et al., 2007b). Briefly, mice were anesthetized with isoflurane (5% induction, 2% maintenance) and placed on
a stereotaxic frame. After a midline skin incision, a 5 mm left lateral
craniotomy was made using a motorized drill. Controlled cortical impact
was produced with an electromagnetic impact device using a 3-mmdiameter metal tip. The impact was centered at 2.7 mm lateral to midline
and 3.0 mm anterior to lambda. Injury severities of 1.0 mm (n ⫽ 6), 1.5
mm (n ⫽ 5), and 2.0 mm (n ⫽ 48 total in all experiments) below the dura
were chosen to model mild, mild-moderate, and moderate injuries, respectively. After injury, the impact site was covered with a plastic skull
cap, skin was sutured, and mice were allowed to recover on a heated pad.
Mice were kept at 37°C via a rectal temperature probe and feedback
temperature controller throughout the duration of the surgery (Cell
MicroControls). Temperature control is important because hypothermia alone has been reported to cause tau accumulation and hyperphosphorylation (Planel et al., 2004). Sham mice underwent the same surgical
procedure including anesthesia and craniotomy but were not injured.
Antibodies. Antibodies used are listed in Table 1. To avoid using antimouse secondary antibodies on injured tissues, most monoclonal antibodies were conjugated to biotin or directly labeled. 3D6 was biotinylated
with NHS-LC-biotin from Pierce. Conjugation of 3D6 to Alexa Fluor 596
was done a via commercially available kit (A20185; Invitrogen).
Immunohistochemistry and double immunofluorescence. Immunohistochemical studies were done on paraformaldehyde-fixed, sucroseequilibrated 50 m cryostat sections, as described previously (Mac
Donald et al., 2007a,b). All sections were washed with Tris-buffered saline (TBS) between applications of antibody solutions. Antigen retrieval
with 70% formic acid (3 min) was performed for A␤ and phospho-tau
staining. Nonspecific binding was blocked by incubation in TBS containing 0.25% Triton X (TBS-X) and 3% nonfat dry milk (monoclonal antibodies) or 3% serum (polyclonal antibodies) or 5% BSA (phospho-tau
antibodies). The primary antibody was diluted in 1% nonfat dry milk,
1% serum, or 1% BSA in TBS-X. Antibodies were 3D6 (1 g/ml), pan-A␤
(1 g/ml), A␤40 (0.5 g/ml), A␤42 (5 g/ml), APP (0.5 g/ml), neurofilament (0.5 g/ml), HT7 (0.2 g/ml), polyclonal tau (1 g/ml), polyclonal phospho-tau antibodies (1 g/ml), and PHF1 (1:1000) (Table 1).
Bound antibodies were detected with biotinylated secondary antibodies,
except for 3D6, which was biotinylated. The horseradish peroxidase
method (ABC Elite kit, PK6100; Vector Laboratories) and DAB were
used for visualization of bound antibodies.

Table 1. Summary of antibodies used in this study
Protein

Antibody

A␤

3D6

Epitope

aa 1–5 requiring
free N terminus
m266
aa 13–28
2G3
aa 35– 40
21F12
aa 33– 42
aa 15–30
panA␤
aa 34 – 40
A␤40
aa 36 – 42
A␤42
APP
APP
Full-length, C terminal
Tau
HT7
panTau
pAb Tau
panTau
Tau46
panTau
AT8
pS199, pS202, pT205
AT100
pS212, pT214
AT180
pT231
S199
pS199
T205
pT205
T231
pT231
S396
pS396
S422
pS422
PHF1
pS396/pS404
Neurofilament NF-L
NF-L 68kD
␣-Tubulin ␣-Tubulin/C terminal
Tubulin

Host/application

Source

Mouse/IHC, ELISA Eli Lilly and Co.
Mouse/ELISA
Mouse/ELISA
Mouse/ELISA
Rabbit/IHC
Rabbit/IHC
Rabbit/IHC
Rabbit/IHC, WB
Mouse/IHC
Sheep/IHC
Mouse/WB
Mouse/WB
Mouse/WB
Mouse/WB
Rabbit/IHC
Rabbit/IHC
Rabbit/IHC
Rabbit/IHC
Rabbit/IHC
Mouse/IHC
Mouse/IHC
Mouse/WB

Eli Lilly and Co.
Eli Lilly and Co.
Eli Lilly and Co.
Invitrogen
Invitrogen
Chemicon
Invitrogen
Pierce
Pierce
Cell Signaling
Pierce
Pierce
Autogen Bioclear
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Dr. P. Davies
Sigma
Sigma

aa, Amino acids; IHC, immunohistochemistry; WB, Western blot.

In double-labeling studies, primary antibodies were sequentially applied, followed by Alexa Fluor-conjugated secondary antibodies except
for 3D6, which was conjugated to Alexa Fluor 596. Images were obtained
using LSM 5 Pascal software (Zeiss Physiology Software) coupled to an
LSM Pascal Vario 2 RGB confocal system (Zeiss).
Preparation of tissue homogenates for A␤ detection by human-specific
ELISAs. Separate groups of sham (n ⫽ 7) and TBI (2.0 mm, n ⫽ 8) mice
were killed at 24 h after surgery; hippocampi ipsilateral and contralateral
to the impact site (including fimbria and surrounding white matter
tracts) were dounce homogenized in TBS (1:10 w/v). Supernatants were
kept, and pellets were subsequently sonicated in a 1:5 w/v solution of 100
mM sodium carbonate, pH 11, containing 50 mM sodium chloride (carbonate lysates). Finally, remaining pellets were homogenized in 1:5 w/v
5M guanidine hydrochloride, rotated at room temperature for 3– 4 h
(guan lysates). All buffers used for homogenization contained protease
and phosphatase inhibitor mixtures (Roche). Supernatants and pellets
from all tissue suspensions were obtained by spinning at 13,300 ⫻ g for
20 min at 4°C. Protein concentrations were determined via the BCA
method (Pierce Biotech). TBS, carbonate, and guanidine lysates prepared above were tested for A␤ contents using a human-specific A␤
ELISA, as described (Cirrito et al., 2003; Kang et al., 2007). Capture
antibodies were m266 for the total A␤1-x ELISA, 2G3 for the A␤1-40
ELISA, and 21F12 for the A␤1-42 ELISA. The detection antibody was
3D6-biotin. These antibodies were gifts from Eli Lilly and Co.
Preparation of tissue homogenates for tau Western blotting and ELISAs.
Separate groups of sham (n ⫽ 7) and injured (2.0 mm, n ⫽ 8) 3xTg-AD
mice were killed at 24 h by rapid decapitation. Bilateral hippocampi were
dissected, immediately frozen, and stored at ⫺80°C. Frozen hippocampi
were homogenized in modified RIPA buffer containing protease and
phosphatase inhibitor mixtures (Roche), as described (Cirrito et al.,
2003). After preclearing samples with protein-G Sepharose beads to
remove endogenous mouse IgG, equal amounts of samples were electrophoresed on 10% BisTris NUPAGE gels (Invitrogen). After transfer, 0.2m-pore nitrocellulose membranes were blocked with 5% nonfat dry
milk in 50 mM Tris, pH 7.6, buffer containing 150 mM NaCl and 0.1%
Tween 20 (TBS-T) for 1 h, and probed with AT8 (1:1000), AT100 (1:
1000), or AT180 (1:1000) in 5% BSA TBS-T overnight at 4°C. Sheep-␣mouse HRP (1:12,000; GE Healthcare) and the ECL Advance Western
Blotting kit (GE Healthcare) were used to detect bound antibodies. Blots
were stripped and reprobed for total tau using Tau46 antibody (1:1000).
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0.2-m-pore nitrocellulose membrane. After
transfer, membranes were blocked in 3% nonfat dry milk in TBS-T for 1 h at room temperature. After washing in TBS-T three times, 5
min each, membranes were incubated with
polyclonal APP antibody (0.25 g/ml) in
blocking buffer overnight at 4°C. Bound antibodies were detected with HRP-conjugated
donkey-␣-rabbit IgG (1:10,000; GE Healthcare) and the ECL Advance Western Blotting
detection kit (GE Healthcare). Blots were
stripped and reprobed with anti-␣-tubulin (1
g/ml) for loading control. Images were taken
on film and scanned.
Compound E treatment. To prevent posttraumatic intra-axonal A␤ accumulation, mice
were treated with intraperitoneal injections of
vehicle or Compound E (CmpE), a smallmolecule inhibitor of ␥-secretase (10 mg/kg;
Axxora) (Seiffert et al., 2000; Olson et al., 2001;
Grimwood et al., 2005; Yang et al., 2008; Yan et
al., 2009). One group of mice received CmpE
(n ⫽ 8) or 0.8% DMSO vehicle (n ⫽ 7) starting
at 1 h before injury, then again at 5, 11, and 17 h
after injury. These mice were killed 24 h after
injury. Another group of mice received 4
CmpE (n ⫽ 7) or vehicle (n ⫽ 7) injections in
the first 24 h as noted above, followed by injections twice daily until 7 d after injury. A total of
10 mg/kg Compound E was used because this
dose has been shown to inhibit cortical
␥-secretase activity in guinea pigs by 71 ⫾ 4%,
measured ex vivo (Grimwood et al., 2005). Furthermore, the frequent dosing regimen was
used because of the short half-life of Compound E: ⬃5– 6 h (Yan et al., 2009). Last, this
relatively high dose was also chosen because of
the presence of the presenilin1 (PS1) M146L
mutation in 3xTg-AD mice, as PS1 mutations
have been shown to have diminished response
to ␥-secretase inhibition (Czirr et al., 2007).
Mice tolerated these dosing regimens well
without additional weight loss, lethargy, or unexpected mortality.
Stereological quantification. Stereological
methods were available via StereoInvestigator
version 8.2 software. All assessments were
made by a single investigator (H.T.T.) blinded
to injury status and treatment regimens of experimental animals. The optical fractionator
Figure 1. Controlled cortical impact TBI caused A␤ accumulation in ipsilateral fimbria/fornix of young 3xTg-AD mice. A–C, A␤
method was used for quantification of total
immunohistochemistry from an injured 3xTg-AD mouse, a sham 3xTg-AD mouse, and an injured wild-type mouse, respectively.
numbers of markers of interest per cubic milScale bar, 2 mm. D–O, Higher magnification of the ipsilateral fimbria/fornix (A–C, boxes). Scale bar, 50 m. The presence of
limeter of tissue. Details on this stereological
intra-axonal A␤ in the ipsilateral fimbria/fornix of a moderately injured 3xTg-AD mouse was confirmed using panA␤, a polyclonal
method have been described (Mac Donald et
antibody against amino acids 15–30 of A␤ (D–F ); 3D6, a monoclonal N-terminus antibody against amino acids 1–5 of A␤ (G–I );
al., 2007a). Briefly, for quantification of A␤40A␤40, a polyclonal C-terminus antibody against amino acids 35– 40 of A␤ (J–L); and A␤42, a polyclonal C-terminus antibody
positive axonal varicosities in ipsilateral fimagainst amino acids 35– 42 of A␤ (M–O). No A␤ immunoreactivity was observed in sham 3xTg-AD mice and injured wild-type
bria and tau-positive somata in ipsilateral
mice. P, No A␤ immunoreactivity was observed in injured 3xTg-AD mice when primary antibody was omitted. Q, Schematic of
amygdala, a 200 ⫻ 200 m sampling grid and a
anti-A␤ antibodies used.
75 ⫻ 75 m counting frame were used. For
quantification of total tau, APP, panA␤, and
phospho-S199-positive puncta in ipsilateral
Blots were scanned, and densitometry was performed via Image J (NIH).
fimbria, a 300 ⫻ 300 m grid and a 40 ⫻ 40 m counting frame were
Total and phospho-S199 tau ELISAs were performed per the manufacused. For PHF1-positive puncta in the fimbria, a 200 ⫻ 200 m grid and
turer’s instructions (Invitrogen).
a 50 ⫻ 50 m counting frame were used. A dissector height of 15 m and
Preparation of tissue homogenates for Western blotting of APP. Bilateral
guard zones of 2.5 m were used for all measurements. Four sections per
cerebellar tissue was homogenized in modified RIPA buffer containing
mouse, each separated by 300 m, were used for these estimations. These
protease inhibitor mixtures (Roche), as described (Cirrito and Holtzsections spanned approximately bregma ⫺1.06 to ⫺1.96 mm (Franklin
man, 2003). Protein concentrations were determined via the BCA
and Paxinos, 1997). The spherical probe (also known as “space balls”)
method (Pierce Biotech). Equal amounts of samples were electrophomethod was used for quantification of the total length of tau immunoresed on 4 –12% BisTris NuPAGE gels (Invitrogen) and transferred to
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reactive processes in the dorsal contralateral
CA1 region (Mouton et al., 2002). A sampling
grid of 250 ⫻ 250 m and a hemispherical
probe with 17 m radius were used. Three sections per mouse from approximately bregma
⫺1.46 to ⫺2.06 mm were used for this
quantification.
Statistical methods. All data were analyzed
using Prism 5.0 (GraphPad Software). ShapiroWilk normality tests were used to assess the
normal distribution of each data set. Mann–
Whitney U tests were used to compare levels of
A␤ and phospho-tau in hippocampal lysates of
injured and sham 3xTg-AD mice, since the distribution of data was not normal. For pairwise
comparisons of quantitative immunochemical
data (e.g., injured vs sham), one-sided Student’s t tests were used in these cases because
unidirectional hypotheses were prespecified.
For changes of either A␤ or tau pathology as a
function of injury severities, one-way ANOVAs
with Newman–Keuls post tests were used. Values are means ⫾ SEM. Statistical significance
was set to p ⬍ 0.05.

Results

Intra-axonal A␤ accumulation after
TBI in 3xTg-AD mice
Acute intra-axonal A␤ accumulation is a
prevalent feature of human traumatic axonal injury (D. H. Smith et al., 2003; Uryu et
al., 2007; Chen et al., 2009). Because of the
age-related intra-axonal A␤ accumulation
in 3xTg AD mice, we hypothesized that
these animals would be useful in the assessment of TBI-related axonal A␤ pathology.
More specifically, we hypothesized that experimental TBI would accelerate intra- Figure 2. Controlled cortical impact TBI resulted in increased levels of relatively insoluble A␤ in 3xTg-AD mice. Ipsilateral (Ipsi) and
axonal A␤ pathology in young 3xTg-AD contralateral(Contra)hippocampaltissuesofinjured(2.0mm)andsham3xTg-ADmiceweresequentiallyhomogenizedinTBS,carbonate,
mice. To test this hypothesis, we subjected andguanidinebuffers.TBSandcarbonatelysatescontainmostlysolubleA␤ species;guanidinelysatesarecomposedofrelativelyinsoluble
these mice to controlled cortical impact TBI, A␤ species. A, Total A␤ levels in TBS lysates of ipsilateral and contralateral hippocampi (Hip) of sham and injured mice. B, Total A␤ levels
as detailed (Brody et al., 2007). Mice were in carbonate lysates of ipsilateral and contralateral hippocampi of sham and injured mice. C, Total A␤ levels in guanidine lysates of
subjected to moderately severe injury: 2.0 ipsilateral and contralateral hippocampi of sham and injured mice. Significantly more total A␤ levels were observed in ipsilateral hipmm below the dura. This resulted in signif- pocampibutnotcontralateralhippocampiofinjuredthanshammice(***p⫽0.0047,Mann–WhitneyUtest).D,A␤1-40.E,A␤1-42 levels
icant hippocampal damage and behavioral inguanidinelysatesofipsilateralhippocampiofshamandinjuredmice.SignificantlymoreA␤1-40 andatrendtowardanincreaseinA␤1-42
deficits but low mortality, as described were observed in ipsilateral guanidine hippocampal lysates of injured compared with sham mice (*p ⫽ 0.013; ns, not significant; Mann–
Whitney U test). n ⫽ 7– 8 mice per group. Error bars represent mean ⫾ SEM.
(Brody et al., 2007). Mice were killed at 24 h
after TBI; their brains were then processed
(Fig. 1 P). No such axonal A␤ pathology was observed in sham
and examined immunohistochemically for A␤ pathology. Negative
(noninjured), age-matched 3xTg-AD mice (Fig. 1B,E,H,K,N), nor
controls included age-matched, sham 3xTg-AD mice (which underin injured wild-type mice (Fig. 1C,F,I,L,O). A␤ was also observed in
went the same anesthesia and surgical procedures but were not inpericontusional hippocampal commissure, corpus callosum, and
jured), injured wild-type B6/SJL mice (2.0 mm), and omission of
the external capsule of injured 3xTg-AD mice, although to a lesser
primary antibodies. The positive controls for A␤ staining were brain
extent than the fimbria/fornix (data not shown).
slices from 20-month-old PDAPP mice (Games et al., 1995).
To further confirm the immunohistochemical findings, humanWe found A␤ accumulations in pericontusional white matter
specific
A␤1-x, A␤1-40, and A␤1-42 ELISAs were used to assess A␤
of injured, young 3xTg-AD mice. The ipsilateral fimbria/fornix
levels
in
hippocampal lysates of these moderately injured and
appeared to have the most prominent A␤ accumulation (Fig.
sham
3xTg-AD
mice. Both ipsilateral and contralateral hip1 A). These A␤ accumulations had spheroidal and “beads-on-apocampi
were
assessed.
These tissues were subjected to serial hostring” morphologies, consistent with the morphology of injured
mogenization in TBS, carbonate, and 5M guanidine. This serial
axons (Fig. 1 D, G, J, M ). The specificity of this A␤ staining was
homogenization method produces extracts enriched in soluble
confirmed with four A␤-specific antibodies: pan-A␤ against
A␤ from the extracellular compartment, soluble A␤ from intraA␤15-30 (Fig. 1 D), monoclonal 3D6 against A␤1-5 (Fig. 1G), polycellular compartments, and residual insoluble A␤, respectively.
clonal C-terminal antibody against A␤35-40 (Fig. 1 J), and polyAlthough there were similar levels of total A␤ (A␤1-x) in TBS and
clonal C-terminal antibody against A␤35-42 (Fig. 1 M). No A␤
carbonate lysates in both ipsilateral and contralateral hipstaining was observed when primary antibodies were omitted
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Previous studies have found that more
severe TBI results in more APP accumulaA
B
C
D
tion in damaged axons (Blumbergs et al.,
1995; Bramlett et al., 1997). Since A␤ is
derived from proteolytic cleavage of APP
and accumulates in axons of 3xTg-AD
mice after TBI, we hypothesized there
would be a correlation between axonal inE
F
G
H
jury severity and extent of A␤ accumulation in these mice. To test this hypothesis,
we performed additional mild (1.0 mm
impact below dura) and mild-moderate
(1.5 mm impact below dura) injuries on
3xTg-AD mice. We compared A␤- and
I
J
K
L
APP-labeled axonal pathologies among the
mild, mild-moderate, and moderate (2.0
mm) TBI groups using immunohistochemistry and stereological quantification.
We found that both APP and A␤ accuM
N
O
mulations in pericontusional white mat***
250000
***
ter were dependent on injury severity in
250000
r2=0.53
500000
ns
ns
p=0.0015
young 3xTg-AD mice. Specifically, few in200000
***
200000
400000
**
jured axons stained for APP were found
150000
in the ipsilateral fimbria/fornix of mildly
150000
300000
injured 3xTg-AD mice (1.0 mm) (Fig.
100000
100000
200000
3 B, F ). Many more APP-stained axonal
50000
varicosities were observed in the same re50000
100000
gion in the other injured groups (1.5 and
0
0
0
2.0 mm) (Fig. 3C, D, G,H ), but none in the
0
100000 200000 300000 400000 500000
APP+ varicosities
sham injured ones (Fig. 3 A, E). Furtherin fimbria (#/mm3)
more, we found a parallel relationship between the extent of the axonal injury and
NF-L68
Merge
Aβ
the amount of intra-axonal A␤ in the fimAβ
APP
Merge
P
Q
bria/fornix (Fig. 3I–L). Markedly fewer
APP- and A␤-stained varicosities were
observed in other injured white matter
regions such as the ipsilateral pericontusional hippocampal commissure, ipsilateral
Figure 3. A␤ accumulation varied with injury severity and colocalized with markers of axonal injury in 3xTg-AD mice. A–D, APP external capsule, and ipsilateral corpus calimmunohistochemistry (IHC) of sham, mildly (1.0 mm), mild-moderately (1.5 mm), and moderately (2.0 mm) injured, young losum (data not shown). In these other
3xTg-AD mice. Scale bar, 2 mm. E–H, Higher magnification of axonal injury detected by APP IHC in the ipsilateral fimbria (A–D, regions, the extent of both APP and A␤
boxes). Scale bar, 50 m. I–L, Intra-axonal A␤ IHC in the ipsilateral fimbria using pan-A␤ antibody against A␤15-30. M, Stereo- staining was similarly dependent on inlogical quantification of numbers of APP-stained varicosities per cubic millimeter of the ipsilateral fimbria as a function of injury jury severity (data not shown).
severity. N, Stereological quantification of numbers of A␤-stained varicosities per cubic millimeter of the ipsilateral fimbria as a
To quantitatively characterize the obfunction of injury severity. Error bars represent mean ⫾ SEM. **p ⬍ 0.01; ***p ⬍ 0.005, one-way ANOVA with Newman–Keuls
served relationship between injury severities
post hoc test. ns, Not significant; Mild-Mod, mild-moderate. O, Pearson’s correlation of numbers of A␤- and APP-stained varicosand the extent of APP and A␤ accumulaities in injured fimbria; r 2 ⫽ 0.53, p ⫽ 0.0015. n ⫽ 5– 6 mice per injury severity. P, Colocalization of A␤ with APP in injured
fimbria of a 3xTg-AD mouse. Scale bar: 50 m. Q, Colocalization of A␤ with neurofilament light chain 68 kDa (NF-L68), another tions in injured axons of the fimbria/fornix,
marker of axonal injury, in injured fimbria of a 3xTg-AD mouse. A␤ was detected with monoclonal 3D6 antibody conjugated to we used the optical fractionator stereologiAlexa Fluor 594 (red). This antibody requires a free N terminus of A␤ for binding and does not cross-react with APP. APP and NF-L68 cal method. We found significantly more
APP-stained varicosities in the mildwere visualized with a secondary antibody conjugated to Alexa 488 (green).
moderate and moderate TBI groups compared with the mild TBI group (Fig. 3M)
pocampi (Fig. 2 A, B), a significant increase in insoluble total A␤
(one-wayANOVA,p⬍0.0001).Therewasatrendtowardanincreasing
was detected in 5M guanidine ipsilateral hippocampal lysates of
number of APP-stained varicosities in the moderate TBI group (2.0
injured compared with sham 3xTg-AD (Mann–Whitney U test,
mm) compared with the mild-moderate TBI group (1.5 mm), but this
p ⫽ 0.0047) (Fig. 2C). There was a nonsignificant trend toward
was not statistically significant (Fig. 3M). A similar relationship between
increased guanidine total A␤ levels in the contralateral hipinjury severities and numbers of A␤-stained varicosities was observed:
pocampi of injured mice compared with sham (Fig. 2C). Furtherthemoreseveretheinjury,themoreintra-axonalA␤ accumulation(Fig.
more, we found a significant increase in A␤1-40 and a trend
3N) (one-way ANOVA,p ⫽ 0.0005). There was a statistically significant
toward increased A␤1-42 in the ipsilateral hippocampal lysates of
positive correlation between the numbers of APP- and A␤-stained varinjured 3xTg-AD mice (Fig. 2 D, E). Overall, these data are conicosities (Fig. 3O) (Pearson r 2 ⫽ 0.53, p ⫽ 0.0015).
cordant with the immunohistochemical evidence of intracellular
To determine definitively whether these accumulations of A␤
A␤ accumulation after TBI in these mice.
were found within injured axons, we performed double-immuno-
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fluorescence labeling of A␤ and APP and
separate double immunofluorescence with
the 68 kDa neurofilament light chain subunit, NF-L68. APP and NF-L68 are well
established axonal markers, and accumulations of both proteins are robust signatures
of axonal injury (Gennarelli et al., 1982;
Yaghmai and Povlishock, 1992; Gentleman
et al., 1993; Grady et al., 1993; Christman et
al., 1994; Sherriff et al., 1994; Graham et al.,
1995; Povlishock and Christman, 1995;
Chen et al., 1999; Smith et al., 1999; Stone et
al., 2000, 2001; Marmarou et al., 2005).
They have been shown to extensively colocalize with A␤ in injured axons from human
TBI patients (D. H. Smith et al., 2003; Uryu
et al., 2007; Chen et al., 2009). We found
that essentially all A␤-immunoreactive axonal varicosities in injured 3xTg-AD mice
were also positive for APP and NF-L68 on
confocal microscopy (Fig. 3P,Q). A␤ labeling was performed using the monoclonal
anti-A␤ antibody 3D6 directly conjugated
to Alexa Fluor 594; 3D6 does not cross-react
with APP as it requires a free N terminus to
bind (Johnson-Wood et al., 1997). No such
colocalization was observed in sham
3xTg-AD mice (data not shown), nor when
one of the primary antibodies was omitted
(data not shown). Thus, controlled cortical
impact TBI in 3xTg-AD mice reproduced
one of the hallmark features of human
post-TBI neurodegenerative pathology:
intra-axonal A␤ accumulation at sites of
traumatic axonal injury.
To summarize, intra-axonal A␤ accumulation appeared consistently in 3xTg-AD
mice after experimental TBI. This intraaxonal A␤ appeared to be in a relatively
insoluble form. Moreover, A␤ colocalized
with markers of axonal injury and correlated with severity of axonal injury.

Ipsilateral
Amygdala

S

T

U
Contralateral
CA1

Figure 4. Controlled cortical impact TBI accelerated tau pathology in young 3xTg-AD mice. Total tau (independent of phosphorylation state) was detected with polyclonal total tau antibody (pAb tau) and HT7 monoclonal antibody. A–C, pAb tau staining
in injured 3xTg-AD mice, sham 3xTg-AD mice, and injured wild-type mice, respectively. D–F, Higher magnification of the ipsilateral fimbria (A–C, black boxes). G–I, Higher magnification of the ipsilateral amygdala (A–C, green boxes). J–L, Higher magnification of the contralateral CA1 (A–C, purple boxes). M–U, Total tau staining using HT7 antibody. More tau-positive puncta were
observed in ipsilateral fimbria of injured 3xTg-AD mice compared with sham 3xTg-AD mice. More tau-positive somata were present
in ipsilateral amygdala of injured compared with sham 3xTg-AD mice. More tau-positive processes were also observed in the contralateral
CA1 of injured compared with sham 3xTg-AD mice. No tau immunoreactivity was observed in injured wild-type mice.

Increased total tau and phospho-tau
immunoreactivity after TBI in
3xTg-AD mice
We next investigated the effects of TBI on
tau accumulation and phosphorylation in
the same injured and sham 3xTg-AD mice.
We first performed immunohistochemistry using polyclonal tau antibody (pAb Tau) and monoclonal HT7, which recognize both normal and hyperphosphorylated human tau. Negative controls
included injured wild-type mice and omission of primary antibodies. Brain slices from 12-month-old 3xTg-AD mice served as a positive control.
In the pericontusional fimbria/fornix, abnormal punctate tau
immunoreactivity was observed after moderate TBI in 3xTg-AD
mice (Fig. 4A,D). There was minimal tau staining in the same region
of sham injured mice (Fig. 4B,E) and none in moderately injured
wild-type mice (Fig. 4C,F). Interestingly, there were two additional
regions in which there were marked increases in tau immunoreactivity in injured compared with sham 3xTg-AD mice. These were
the ipsilateral amygdala and contralateral CA1 regions (Fig.

4 A, B,G, H, J,K ). Tau immunoreactivity in the amygdala had a
perinuclear cytoplasmic distribution, whereas that in the contralateral CA1 took the appearance of elongated neurites. These
regions are distant from the site of injury but are anatomically
connected to the ipsilateral hippocampus via the ipsilateral fimbria/fornix tract (Witter and Amaral, 2004). Similar patterns of
tau staining were observed in injured and sham 3xTg-AD mice
when monoclonal HT7 against total tau was used (Fig. 4 M, N, P, Q,S,T ). No total tau immunoreactivity was observed in
injured wild-type mice (Fig. 4C, F, I, L, O, R, U ). Total tau immunoreactivity in the ipsilateral hippocampus was not significantly
affected by TBI in these mice (data not shown).
Next, we examined the effects of varying injury severity on
total tau pathology in 3xTg-AD mice (Fig. 5B–D). Abnormal
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eral amygdala compared with other TBI and
sham groups (Fig. 5R) (one-way ANOVA,
p ⫽ 0.008). Likewise, tau-positive neurite
length density in the contralateral CA1 of
these moderately injured mice was significantly greater than the length density in the
other groups (Fig. 5S) (one-way ANOVA,
p ⫽ 0.0079).
To test whether TBI increased the exIpsilateral
tent of tau phosphorylation in 3xTg-AD
Fimbria
mice, we performed additional immunohistochemical studies using polyclonal
antibodies against phosphorylated tau in
sham and moderately injured mice. Injured mice exhibited more phospho-tau
Ipsilateral
Amygdala
staining than sham mice for all the
phospho-tau antibodies used. Specifically, phospho-S199 tau was observed in
ipsilateral hippocampal CA1 and fimbria
of moderately injured mice (Fig. 6 A, C).
Contralateral
Immunoreactivity
for phospho-T205 was
CA1
prominent in ipsilateral fimbria only (Fig.
6 E). Tau also appeared to be heavily phosphorylated at T231, S396, and S422 in fimQ
R
S
bria of 3xTg-AD mice after TBI (Fig.
***
6G,I,K). No phospho-tau immunoreactiv***
**
*
**
**
*
ity was observed in sham 3xTg-AD mice at 6
200000
25000
5000
*
*
**
months of age (Fig. 6B,D,F,H,J,L).
20000
4000
150000
To further confirm these findings, sepa15000
3000
rate groups of sham and moderately injured
100000
mice were killed at 24 h by rapid decapita10000
2000
tion. Bilateral hippocampi were quickly re50000
5000
1000
moved and frozen. Tissue was homogenized
in RIPA buffer and subjected to Western
0
0
0
blotting using the monoclonal AT8 antibody against phosphorylated tau at S199 or
S202 and T205, the AT100 antibody against
TBI
TBI
TBI
phosphorylated tau at T212 and S214, and
Figure 5. Tau pathology varied with injury severity in young 3xTg-AD mice. A–D, pAb Tau immunohistochemistry of sham, the AT180 antibody against phosphorylated
mildly (1.0 mm), mild-moderately (1.5 mm), and moderately (2.0 mm) injured, young 3xTg-AD mice. Scale bar, 2 mm. E–H, Higher tau at T231 (Mercken et al., 1992). Blots
magnification of tau staining in the ipsilateral fimbria (A–D, black boxes). Scale bar, 50 m. I–L, Higher magnification of tau were stripped and reprobed with the Tau46
staining in the ipsilateral amygdala (A–D, green boxes). M–P, Higher magnification of tau staining in the contralateral CA1 (A–D, antibody to quantify total tau.
purple boxes). Q, Stereological quantification of numbers of tau-stained punctate varicosities per cubic millimeter of the ipsilateral
We found marked increases in the
fimbria as a function of injury severity. R, Stereological quantification of numbers of tau-stained somata per cubic millimeter of the densities of AT8-, AT100-, and AT180ipsilateral amygdala as a function of injury severity. S, Stereological quantification of tau-immunoreactive neuritic processes per cubic immunoreactive bands in injured commillimeter of the contralateral CA1 as a function of injury severity. n ⫽ 5– 6 mice per injury severity. Error bars represent mean ⫾ SEM. pared with sham 3xTg-AD mice, indicating
*p ⬍ 0.05; **p ⬍ 0.01; ***p ⬍ 0.005, one-way ANOVA with Newman–Keuls post hoc test. Mild-Mod, mild-moderate.
an increase in levels of tau phosphorylation
(Fig. 6M–O). Total tau levels in these samtau-positive puncta in the ipsilateral fimbria appeared to inples appeared slightly lower in the injured mice (Fig. 6M). Overall,
crease in an injury-severity-dependent manner (Fig. 5F–H ).
there were approximately twofold increases in the ratio of
There was minimal tau staining in the same region of sham
AT8-, AT100-, and AT180-immunoreactive phospho-tau
injured mice (Fig. 5 A, E). Only in the moderate TBI group
band densities to total tau band densities after TBI in 3xTg-AD
were there more tau-positive somata in the ipsilateral
mice (Fig. 6M–O) (Mann–Whitney U test, p ⬍ 0.05). No such
amygdala and tau-positive neurites in the contralateral CA1
immunoreactivity for tau was observed when primary anti(Fig. 5I–P). No tau immunoreactivity was observed in injured
body was omitted (data not shown). No increases in tau phos3xTg-AD mice when the primary antibody was omitted (data
phorylation were detected in contralateral hippocampal
not shown).
lysates (data not shown).
Quantitative analyses of tau immunoreactivity in these reIn summary, experimental TBI caused increased tau immunoregions using stereology confirmed the qualitative histological findactivity in 6-month-old 3xTg-AD mice. Notably, the spatial distribuings. There were significantly more tau-positive puncta in ipsilateral
tion of TBI-related changes in tau immunoreactivity was distinct
fimbria/fornix as the injury became more severe (Fig. 5Q) (one-way
from those of postinjury A␤. Levels of tau phosphorylation were
significantly increased after TBI, based on both biochemical and
ANOVA, p ⬍ 0.0001). In the moderately injured group (2.0 mm),
immunohistochemical analyses.
there was a significant increase in tau-positive somata in the ipsilat-
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Effects of ␥-secretase inhibition on
Moderate TBI
Sham
posttraumatic A␤ accumulation and
3
M TBI Sham
tau pathologies
***
The findings that both A␤ and tau pathologies were accelerated by controlled corti2
cal impact allowed us the opportunity to
investigate the interaction between A␤
1
and tau in the setting of TBI.
To investigate the interaction between
A␤ and tau pathologies, we blocked A␤
0
production using a ␥-secretase inhibitor.
␥-Secretase is one of the canonical enzymes required for proteolytic processing
3
of APP to form A␤ (Selkoe, 2001). If tau is
N TBI Sham
*
downstream of A␤ in the setting of TBI,
we expected to see amelioration of tau ab2
normalities after blocking A␤ production.
However, if tau and A␤ are independently
1
affected by trauma, blocking A␤ production should have no effects on tau pathology observed after TBI in these mice.
0
We first confirmed that inhibition of
␥-secretase blocked intra-axonal A␤ buildup
in 3xTg-AD mice after moderate TBI. We
3
treated injured mice with CmpE, a smallO TBI Sham
*
molecule inhibitor of ␥-secretase (Seiffert
et al., 2000; Olson et al., 2001; Grimwood
2
et al., 2005; Yang et al., 2008; Yan et al.,
2009) or DMSO vehicle. Mice received
1
intraperitoneal injections of 10 mg/kg
CmpE or vehicle at 1 h before injury and
then again at 5, 11, and 17 h after injury.
0
The frequent dosing regimen was used because of the short half-life of CmpE (Yan
et al., 2009). A relatively high dose was
used as a result of the presence of a PS1
mutation in 3xTg-AD mice, since such Figure 6. Controlled cortical impact TBI increased levels of phospho-tau immunoreactivity in ipsilateral hippocampi and fimbria
mutations may result in diminished re- of young 3xTg-AD mice. A–D, Tau staining of moderate TBI (2.0 mm) and sham 3xTg-AD mice using a polyclonal antibody against
sponse to ␥-secretase inhibition (Czirr phosphorylated tau at S199. Scale bar, 50 m. A, B, Ipsilateral hippocampal CA1. C, D, Ipsilateral fimbria. E–L, Phospho-tau
staining in fimbria of TBI and sham 3xTg-AD mice using polyclonal antibodies against tau phosphorylated at T205 (E, F ), T231 (G,
et al., 2007). In our first experiment, mice H ), S396 (I, J ), and S422 (K, L). M, Representative AT8 Western blot of ipsilateral hippocampi from 2.0 mm TBI and sham 3xTg-AD
were killed at 24 h after injury. One group mice. AT8 blots were stripped and reprobed with Tau46 antibody for total tau. A significant increase in ratio of AT8 to Tau46 band
of CmpE- and vehicle-treated mice was densities was observed after TBI (***p ⫽ 0.0006, Mann–Whitney U test). N, Representative AT100 Western blot of ipsilateral
used for immunohistochemical analysis, hippocampi from 2.0 mm TBI and sham 3xTg-AD mice. A significant increase in ratio of AT100 to Tau46 band densities was
and another group was used for biochem- observed after TBI (*p ⫽ 0.03, Student’s t test). O, Representative AT180 Western blot of ipsilateral hippocampi from 2.0 mm TBI
ical assessment. For histology, we used and sham 3xTg-AD mice. A significant increase in ratio of AT180 to Tau46 band densities was observed after TBI (*p ⫽ 0.03,
polyclonal antibody A␤40 for A␤ immuno- Student’s t test). n ⫽ 7– 8 mice per group. Error bars represent mean ⫾ SEM.
histochemistry in this experiment since
0.0001). Biochemical quantification of RIPA-soluble A␤40 in
␥-secretase cleavage of APP is at the C terminus of A␤; N-terminal
ipsilateral hippocampi and surrounding white matter showed
anti-A␤ antibodies would still recognize the longer APP fragments
similar reduction (CmpE-treated mice, 32.5 ⫾ 2.87 pg/mg vs
remaining after ␥-secretase inhibition. We stained these brains for
vehicle-treated mice, 217.9 ⫾ 52.1 pg/mg; one-sided t test, p ⫽
APP to assess the extent of axonal injury. We also assessed full-length
0.0013). CmpE effectively blocked ␥-secretase activity in the set␣-CTFs and ␤-CTFs (APP fragments resulted from cleavage of APP
ting of TBI, as evidenced by similar levels of full-length APP but
by ␣- and ␤-secretases, respectively) in the cerebellar lysates of the
increased ␣-CTFs and ␤-CTFs in cerebellar lysates of mice with
same mice via Western blot to demonstrate that CmpE was effective
CmpE treatment (data not shown). Furthermore, numbers of
at inhibiting brain ␥-secretase activity. For the biochemical assessAPP-stained varicosities were similar between treatment groups
ment, we killed mice by rapid decapitation and homogenized ipsi(Fig. 7 F, G,J ). This finding demonstrated that ␥-secretase inhibilateral hippocampi in RIPA buffers. RIPA lysates of CmpE- and
tion by CmpE specifically reduced proteolytic A␤ production,
vehicle-treated mice were used to determine levels of A␤40 by ELISA.
rather than reducing A␤ pathology by affecting extent of axonal
CmpE treatment almost completely prevented intra-axonal
injury in these injured mice.
A␤ accumulation in ipsilateral fimbria of injured 3xTg-AD mice
CmpE treatment had no effect on tau pathologies in 3xTg-AD
(Fig. 7 A, B). Stereological quantification of numbers of A␤40mice killed at 24 h after TBI, despite the 90% reduction in A␤
positive axonal varicosities showed ⬃90% reduction in CmpEaccumulation (Fig. 8). We assessed total and phosphorylated tau
versus vehicle-treated mice (Fig. 7E) (one-sided t test, p ⬍
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mice (CmpE group, 61.1 ⫾ 9.2 pg/mg vs
vehicle group, 57.9 ⫾ 13.9 pg/mg; Student’s
E
t test, p ⫽ 0.85). Ipsilateral hippocampi of
200000
*** **
CmpE- and vehicle-treated mice subjected
to Western blotting using AT8 and AT100
150000
antibodies also corroborated these findings
(AT8/Tau 46 ratio for CmpE group, 1.01 ⫾
100000
0.04 vs vehicle group, 1.09 ⫾ 0.07; AT100/
Tau46 ratio for CmpE group, 1.01 ⫾ 0.03 vs
50000
vehicle group, 1.08 ⫾ 0.05). Tau pathologies
in these experimental groups were qualita0
tively and quantitatively similar to those
1d 1 d 7d 7 d
pE icle pE icle
seen in the moderately injured mice that rem
m
C Veh C Veh
ceived neither vehicle nor CmpE (Figs.
J
4 – 6). Thus, it was unlikely that there were
400000
any effects of DMSO vehicle treatment or
the additional handling required for the
300000
injections.
Furthermore, we examined the effects
200000
of CmpE or vehicle treatment on injured
mice up to 7 d after TBI. We chose this
100000
survival period because we found that
both A␤ and tau abnormalities persisted
0
in untreated, injured mice at 7 d after TBI,
although to a lesser extent than those observed at 24 h after TBI. Mice received
CmpE or vehicle injections four times in
Figure 7. Systemic inhibition of ␥-secretase activity with CmpE blocked posttraumatic A␤ accumulation at 1 and 7 d after the first 24 h as described above and then
injury but did not alter the extent of axonal injury. A, B, A␤40 immunohistochemistry (IHC) for injured 3xTg-AD mice receiving twice daily until they were killed at 7 d
CmpE or vehicle (DMSO) treatment killed at 24 h after injury. C, D, A␤40 IHC for injured 3xTg-AD mouse receiving CmpE or vehicle
after injury. We stained brain sections for
treatment for 7 d after injury. E, Stereological quantification of numbers of A␤40-stained varicosities in the ipsilateral fimbria of
A␤40, APP, total tau, phospho-S199, and
injured 3xTg-AD mice receiving either CmpE or vehicle treatment at 1 and 7 d after TBI. These data demonstrated intra-axonal A␤
buildup after TBI could be inhibited by blocking ␥-secretase activity. ***p ⬍ 0.0001; **p ⫽ 0.0015, Student’s t test. F, G, APP IHC PHF1 to assess the effects of CmpE treatof fimbria from injured 3xTg-AD mice treated with CmpE or vehicle killed at 24 h after injury. H, I, APP IHC of fimbria from injured ment on both A␤ and tau abnormalities.
Extended CmpE treatment success3xTg-AD mice treated with CmpE or vehicle for 7 d after injury. J, Stereological quantification of APP-positive axonal varicosities in
ipsilateral fimbria of injured mice treated with CmpE or vehicle killed at 1 and 7 d after TBI. Similar numbers of APP-positive axonal fully blocked the accumulation of the A␤
varicosities in the two treatment groups indicate CmpE treatment did not affect the extent of axonal injury in these mice. n ⫽ 7– 8 in the ipsilateral fimbria/fornix of injured
mice per group. Error bars represent mean ⫾ SEM.
3xTg-AD mice at 7 d (Fig. 7C–E) (onesided t test, p ⫽ 0.001). In vehicle-treated
levels in injured 3xTg-AD mice treated with CmpE or vehicle.
mice, there were still numerous A␤-positive (Fig. 7D) and APPSpecifically, we studied tau pathology histologically with polyclonal
positive (Fig. 7I ) varicosities at 7 d, although the extent of staintotal tau antibody, phospho-S199 antibody against tau phosphorying was reduced compared with 24 h after TBI (Fig. 7 E, J ). Similar
lated at S199, and PHF1 antibody against phosphorylated tau at S396
to the acute CmpE treatment experiments, extended CmpE treatand S404. We also examined tau pathology biochemically via Westment did not alter the extent of axonal injury as assessed by
ern blots using the AT8, AT100, and Tau46 antibodies. Finally, we
numbers of APP-positive varicosities in the ipsilateral fimbria/
investigated total and phospho-S199 levels by ELISA. All assessfornix (Fig. 7H–J ). Furthermore, total tau immunoreactivity in
ments were done in a blinded fashion.
the fimbria, amygdala, and CA1 were not statistically different in
Using quantitative stereological methods as described above,
CmpE- and vehicle-treated mice (Fig. 8C–E,H–J,M–O). Imporwe found that the numbers of total tau-positive puncta in the
tantly, tau phosphorylation at phospho-S199 and PHF1 epitopes
ipsilateral fimbria, the numbers of total tau-stained somata in the
was also unaffected after 7 d of CmpE treatment (Fig. 8R–T,W–Y).
ipsilateral amygdala, and total length density of tau-positive CA1
Thus, we did not observe a delayed effect of inhibition of A␤ accumulation on tau pathology after TBI.
processes were not affected by CmpE treatment in injured
In summary, inhibition of ␥-secretase activity with CmpE suc3xTg-AD mice (Fig. 8 A, B,E–G,J–L,O). Total tau levels in the
cessfully blocked posttraumatic A␤ generation and buildup in inipsilateral hippocampal tissues of injured mice treated with CmpE
jured axons in 3xTg-AD mice but did not affect either local or distant
were not statistically different from those of vehicle-treated mice, as
tau immunoreactivity. This provides experimental evidence that
assessed by human tau ELISA (CmpE-treated mice, 819.7 ⫾ 99.38
posttraumatic acceleration of A␤ and tau pathologies occur indepg/mg vs vehicle-treated mice, 796.6 ⫾ 161.1 pg/mg; Student’s t test,
pendently in this animal model.
p ⫽ 0.9).
The increases in tau phosphorylation after TBI were not affected
Discussion
by CmpE treatment. There were similar numbers of pS199- and
In summary, controlled cortical impact TBI in 3xTg-AD mice
PHF1-positive tau puncta in ipsilateral fimbria of injured mice
recapitulated two key pathological features observed in human
treated with CmpE compared with vehicle-treated mice (Fig. 8P,Q,
TBI patients. First, rapid intra-axonal A␤ accumulation was conT,U,V,Y). Phospho-tau S199 levels in ipsilateral hippocampi assistently detected in an area of axonal injury, the pericontusional
sessed by ELISA revealed similar levels in CmpE- and vehicle-treated
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fimbria. This is similar to the intra-axonal
A␤ accumulation observed in human TBI
patients (D. H. Smith et al., 2003; Ikonomovic et al., 2004; Uryu et al., 2007; Chen
et al., 2009). No such accumulation is expected at this age, and none was seen in
sham-injured mice. Second, increased
tau immunoreactivity was found in
three distinct brain regions of moderately
injured 3xTg-AD mice. There was immunohistochemical and biochemical evidence for increased tau accumulation and
phosphorylation induced by TBI at several epitopes.
Axonal injury appears necessary for
posttraumatic A␤ accumulation in this
model, as the extent of intra-axonal A␤
accumulation correlated well with injury
severity and no A␤ was detected immunohistochemically in areas without axonal
injury. A␤ was found colocalized with the
axonal injury markers APP and NFL-68 in
injured 3xTg-AD mice. Histological findings of A␤ accumulation after TBI were
further confirmed biochemically; there
was approximately twice the amount of
insoluble total A␤ and A␤40 in ipsilateral
hippocampal tissues of moderately injured compared with uninjured mice. The
significant increase in only A␤40 levels after TBI in these mice may be related to the
lack of extracellular A␤ plaques observed
by immunohistochemistry.
In addition to focal injuries, the controlled cortical impact TBI model used in
this study also affected distant regions
such as the contralateral hippocampi and
ipsilateral amygdala. Evidence for this observation included a significant increase
in total tau accumulation in the contralateral CA1 and ipsilateral amygdala of moderately injured mice. Interestingly, there
was not a substantial increase in total tau
accumulation in the ipsilateral hippocampus. Neuronal loss or injury may have
caused release of tau into the extracellular
space where it could not be detected by
immunohistochemistry.
The subacute effects of TBI are evidenced in the persistent immunoreactiv-

Figure 8. Inhibition of posttraumatic A␤ formation by CmpE did not affect tau pathology after moderate (2.0 mm) TBI in young
3xTg-AD mice. A–N, Total tau immunohistochemistry (IHC) in the ipsilateral fimbria (A–D), ipsilateral amygdala (F–I ), and
contralateral CA1 (K–N ) of mice treated with CmpE or vehicle killed at 1 or 7 d after injury. Stereological quantification of total
tau-stained puncta in ipsilateral fimbria (E), total tau-stained somata in ipsilateral amygdala (J ), and total tau-stained neurite

4
length density in contralateral CA1 (O) of injured mice treated
with CmpE or vehicle at 1 and 7 d post TBI is shown. P–S,
Phospho-tau IHC using pS199 antibody. T, Stereological quantification of pS199-positive puncta in ipsilateral fimbria of
mice treated with CmpE or vehicle. U–X, Phospho-tau IHC using PHF1 antibody. Y, Stereological quantification of PHF1positive tau puncta in ipsilateral fimbria of injured mice
treated with CmpE or vehicle. All measures of tau immunoreactivity were not statistically different between CmpE- and
vehicle-treated mice (Mann–Whitney U tests). n ⫽ 7– 8 mice
per group. Error bars represent mean ⫾ SEM.
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ity of APP, A␤, total tau, and phospho-tau in injured 3xTg-AD
mice killed at 7 d after injury. However, there was less APP, A␤,
and total tau immunoreactivity at 7 d compared with 24 h after
TBI, presumably because of progressive cell death and tissue loss
at the affected regions at the later time point. Interestingly, tau
phosphorylation at phospho-S199 and PHF1 epitopes remained
elevated at 7 d after injury. This suggests a possible role for pathological tau on longer-term outcomes after TBI in vivo.
Importantly, inhibition of enzymatic activity of ␥-secretase,
one of the canonical enzymes involved in cleaving APP to form
A␤ under physiological conditions, almost completely eliminated posttraumatic A␤ aggregation in injured 3xTg-AD. However, accelerated tau abnormalities observed after trauma in these
mice appear likely to be independent of A␤, since inhibition of
intra-axonal A␤ buildup did not alter tau pathology. These findings were consistent during the acute (24 h) as well as the subacute (7 d) periods after TBI. This demonstrates the utility of
this controlled cortical impact 3xTg-AD model in the mechanistic investigation of the association between TBI and ADrelated pathology.
Together, these results support a causal relationship between
TBI and acceleration of A␤ and tau pathologies. Our mouse
model is the first small-animal model, of which we are aware, that
reliably and rapidly reproduces these key features of acute human
post-TBI A␤ and tau pathologies. This could be attributable to a
number of reasons. First, previous TBI models using transgenic
mice only used those that overexpress either mutated forms of
APP or tau, not both (Smith et al., 1998; Uryu et al., 2002; Yoshiyama et al., 2005). Second, 3xTG-AD mice also have a
knock-in PS1 mutation, which shifts A␤ accumulation to mostly
intracellular (Mastrangelo and Bowers, 2008) and possibly increases tau phosphorylation (Baki et al., 2004; Dewachter et al.,
2008). Furthermore, methodological differences between our
stereotaxic electromagnetically driven controlled cortical impact
device-based protocol and previously used injury paradigms
could have resulted in different distributions of axonal injury or
other subtle differences in postinjury physiology.
However, there are several limitations of our TBI model. First,
this model produces a central contusion and pericontusional axonal injury. Humans often do sustain contusions with pericontusional axonal injury, but many injuries in humans are diffuse or
multifocal. Nonetheless, axonal injury appears to be a virtually
ubiquitous sequela of TBI (Adams, 1982; Gennarelli et al., 1982;
Gennarelli, 1983, 1993; Adams et al., 1984; Blumbergs et al., 1994,
1995; Geddes et al., 2000), and many types of injuries in humans
have been reported to result in A␤ and tau pathology (Roberts et
al., 1991; Schmidt et al., 2001; D. H. Smith et al., 2003; Ikonomovic et al., 2004; Uryu et al., 2007; McKee et al., 2009). Injured
axons appear to be a major source of A␤ after TBI in humans
(D. H. Smith et al., 2003; Ikonomovic et al., 2004; Uryu et al.,
2007; Chen et al., 2009), pigs (Smith et al., 1999; Chen et al.,
2004), rats (Iwata et al., 2002), and now mice. Therefore, robust
axonal injury and intra-axonal A␤ accumulation lends support to
the validity of our model. An additional mouse injury paradigm
such as fluid percussion or impact acceleration injury that produces more diffuse axonal injury will be required to generalize
our findings.
Second, most humans with TBI do not have a known genetic
predisposition to developing AD-related pathologies, whereas
the 3xTg-AD line has three mutations implicated in familial dementia. This limitation applies to this and other mouse models of
age-related AD pathology as well. The introduction of these mutations seems to be required because of fundamental differences
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between mouse and human coding sequences, differences in gene
regulation, the short life span of the mouse, or a combination of
these. Mice with human wild-type APP, PS1, and tau alleles
“knocked in” to the mouse loci would be useful to differentiate
these possibilities.
Third, whereas axonal tau accumulation has been observed in
a few cases of acute TBI in humans, the effects of injury severity
on axonal tau accumulation, as described in this study, have not
been documented. Likewise, the increased somatic tau accumulation in this model is rarely observed in human TBI (Ikonomovic et al., 2004). Thus, the relevance of these pathologies is not
known.
Fourth, neither this animal model, nor any other small animal
of which we are aware, develops acute posttraumatic extracellular
A␤ plaque pathology. The relative importance of extracellular
versus intracellular A␤ pathologies in the setting of TBI is not
known. Nonetheless, the opportunity to investigate one form of
acute posttraumatic A␤ pathology, acute posttraumatic tau abnormalities, and the interaction of these two pathologies makes
the model presented here a significant advance. Ultimately, full
validation will require predictions made based on the model that
are subsequently confirmed in humans.
The question of whether these pathologies trigger chronic,
progressive neurodegeneration remains to be addressed. Similarly, future studies should be performed to determine whether
these A␤ and tau abnormalities adversely affect behavioral outcomes in 3xTg-AD mice subjected to TBI. If so, preclinical therapeutic trials would be required to determine whether clinically
realistic interventions could ameliorate these deficits (Abrahamson et al., 2006; Loane et al., 2009). The long-term goal would be
to develop treatments that block the adverse effects of AD-related
pathophysiological processes after acute TBI in humans.
Based on our findings, it is most likely that A␤ does not play a
critical role in TBI-induced tau pathology. However, a small fraction of A␤ remained after ␥-secretase inhibition in injured
3xTg-AD mice. Thus, there may be minor, yet toxic, A␤ species
that could ultimately affect tau pathology. Additional studies
should be performed to identify whether such species exist and
whether they do, in fact, accelerate tau pathology in the setting of
TBI. Experiments involving TauP301L-only transgenic mice or
3xTg-AD, BACE⫺/⫺ mice subjected to TBI would provide further insights into effects of TBI on tau pathology. If, as seems
likely, tau pathology is truly independent of A␤ in the setting of
TBI, the underlying mechanisms will require investigation to elucidate additional therapeutic targets. Possible involvement of
GSK3␤, calpain, JNK, and cdk5 cascades on tau pathology could
be considered (Querfurth and LaFerla, 2010).
Apart from its effects on A␤ production, mutant PS1 has been
implicated in other functions such as neuronal calcium dyshomeostasis and regulation of synaptic plasticity (Thinakaran and
Parent, 2004; Mattson, 2010). Since dysregulation of calcium signaling is thought to play an important role in glutamate-induced
excitotoxicity after brain injury (Arundine and Tymianski, 2004;
Szydlowska and Tymianski, 2010), it is possible that the mutant
PS1 in the 3xTg-AD mouse model may exacerbate TBI-induced
neurodegeneration, in addition to its effects on both A␤ and tau
pathologies. Future experiments subjecting PS1 single-transgenic
mouse to brain trauma will be required to elucidate its role in the
context of TBI.
In conclusion, this controlled cortical impact model using
3xTg-AD mice reproduced key features of human post-TBI ADrelated pathology. It will likely allow many mechanistic hypoth-
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eses to be tested and may be useful for preclinical therapeutic
development.
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